Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

365 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France.
de Monteynard LA, Matheron S, Grabar S, de Truchis P, Gilquin J, Pavie J, Launay O, Meynard JL, Khuong-Josses MA, Rey D, Mahamat A, Dray-Spira R, Simon A, Costagliola D, Abgrall S; FHDH-ANRS CO4. de Monteynard LA, et al. Among authors: matheron s. PLoS One. 2018 Oct 31;13(10):e0205385. doi: 10.1371/journal.pone.0205385. eCollection 2018. PLoS One. 2018. PMID: 30379870 Free PMC article.
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.
Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group. Meynard JL, et al. Among authors: matheron s. AIDS. 2002 Mar 29;16(5):727-36. doi: 10.1097/00002030-200203290-00008. AIDS. 2002. PMID: 11964529 Clinical Trial.
Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
Kousignian I, Abgrall S, Duval X, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV. Kousignian I, et al. Among authors: matheron s. J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):50-7. doi: 10.1097/00126334-200309010-00007. J Acquir Immune Defic Syndr. 2003. PMID: 14501793
Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV. Abgrall S, et al. Among authors: matheron s. Clin Infect Dis. 2003 Dec 1;37(11):1517-26. doi: 10.1086/379070. Epub 2003 Oct 29. Clin Infect Dis. 2003. PMID: 14614675
Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy.
Selinger-Leneman H, Matheron S, Mahamat A, Moreau J, Costagliola D, Abgrall S; Clinical Epidemiology Group of the French Hospital Database on HIV (ANRS CO4). Selinger-Leneman H, et al. Among authors: matheron s. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):206-11. doi: 10.1097/QAI.0b013e31815aca91. J Acquir Immune Defic Syndr. 2008. PMID: 17971717
365 results